Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Tempest Therapeutics Inc (TPST)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: TPST (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $9
1 Year Target Price $9
| 0 | Strong Buy |
| 0 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -80.61% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 25.41M USD | Price to earnings Ratio - | 1Y Target Price 9 |
Price to earnings Ratio - | 1Y Target Price 9 | ||
Volume (30-day avg) 2 | Beta -2.33 | 52 Weeks Range 5.35 - 30.03 | Updated Date 06/30/2025 |
52 Weeks Range 5.35 - 30.03 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -18.04 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -73.47% | Return on Equity (TTM) -282.07% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 17002753 | Price to Sales(TTM) - |
Enterprise Value 17002753 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.31 | Shares Outstanding 3682430 | Shares Floating 3433459 |
Shares Outstanding 3682430 | Shares Floating 3433459 | ||
Percent Insiders 0.12 | Percent Institutions 11.74 |
Analyst Ratings
Rating 2 | Target Price 9 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Tempest Therapeutics Inc
Company Overview
History and Background
Tempest Therapeutics, Inc. (TPST) is a clinical-stage oncology company focused on developing therapies that combine both direct tumor killing and immune-mediated mechanisms. Founded in 2011, it has gone through various stages of clinical trials and corporate development to reach its current state. In October 2023, it announced a significant private placement, changing its focus.
Core Business Areas
- Oncology Drug Development: Developing small molecule therapeutics for cancer treatment, focusing on targets that activate the immune system to fight cancer.
Leadership and Structure
Sam Whiting serves as the CEO. Board members include veteran biotech investors and executives. The structure involves research and development teams, clinical operations, and corporate functions.
Top Products and Market Share
Key Offerings
- TPST-1120 (failed, not currently pursued): A PPARu03b1 antagonist being evaluated for treatment of advanced cancers. TPST-1120 was the company's most advanced candidate. As of Nov 2023, the company has announced discontinuing investment in the drug. Competitors include companies developing similar PPARu03b1 antagonists, or other targeted therapies for relevant cancers (such as immunotherapy drugs from Merck, Bristol-Myers Squibb, Roche).
Market Dynamics
Industry Overview
The oncology market is large and competitive, with significant investment in new therapies. The focus is shifting towards personalized medicine and immunotherapies.
Positioning
Tempest Therapeutics sought to position itself by combining tumor killing with immune activation. Post private placement, and with a new lead compound and license from Millenium, the company looks to bring to market new targets. Its competitive advantage lied in a unique approach, but this is unproven.
Total Addressable Market (TAM)
The global oncology market is estimated to be worth hundreds of billions of dollars. Tempest's previous TAM would have been dependent on the specific cancer indications TPST-1120 was targetting. With the new compound and change in strategy, TAM will depend on the focus of the company.
Upturn SWOT Analysis
Strengths
- Experienced leadership team
- Strong intellectual property portfolio (related to previous lead compound TPST-1120; current IP status with Millennium is unknown)
- Novel approach to cancer therapy (Immuno-oncology)
Weaknesses
- Reliance on a single drug candidate (TPST-1120 originally)
- Limited financial resources prior to the private placement.
- High risk of clinical trial failure
- Unproven technology platform
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new cancer indications
- Advancements in personalized medicine
- Successful clinical trial results, leading to approval
- Acquisition target due to new direction/focus
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles and delays
- Failure of clinical trials
- Changes in the healthcare landscape
- Lack of funding
Competitors and Market Share
Key Competitors
- MRK
- BMY
- Roche (ROG.SW)
Competitive Landscape
Tempest Therapeutics faced significant challenges competing with larger, more established pharmaceutical companies. The company is small, and market share is nearly insignificant.
Growth Trajectory and Initiatives
Historical Growth: Prior to 2024, Tempest's growth trajectory was focused on advancing TPST-1120. That trajectory ended. Future growth depends on the new lead compound (licensed from Millennium) and its clinical development.
Future Projections: Future projections are highly uncertain. Analyst estimates are speculative at this stage.
Recent Initiatives: Recent initiatives include discontinuing investment in TPST-1120 and entering a license agreement with Millenium Pharmaceuticals. Future success depends on the success of this partnership.
Summary
Tempest Therapeutics is a high-risk, high-reward biotech company in the early stages of clinical development. The company faces strong competition, regulatory hurdles, and the inherent risks of drug development. The future success of Tempest hinges on the success of its new lead compound and the strength of its new Millenium partnership. The financial situation has improved, but is still dependent on clinical trial results.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC filings
- Company press releases
- Analyst reports
- Company website
- Yahoo Finance
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Information may not be fully up-to-date.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Tempest Therapeutics Inc
Exchange NASDAQ | Headquaters Brisbane, CA, United States | ||
IPO Launch date 2012-11-12 | CEO, President & Director Mr. Stephen R. Brady J.D., LLM | ||
Sector Healthcare | Industry Biotechnology | Full time employees 24 | Website https://www.tempesttx.com |
Full time employees 24 | Website https://www.tempesttx.com | ||
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its clinical-stage lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study. Tempest Therapeutics, Inc. is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.